Kidney Cancer Lincoln NE

Using a combination of the drugs temsirolimus (Torisel) and Bryostatin appears to be safe in patients with metastatic kidney cancer, according to early data from 25 patients in a phase 1 trial. The researchers said a pathway known as mtor signaling promotes tumor cell proliferation and tumor blood vessel development.

Superior Veterinary Care
(402) 438-4500
4640 Bair Ave
Lincoln, NE

Data Provided by:
Clear Vision Eye Care
(402) 742-0399
570 Fallbrook Blvd
Lincoln, NE

Data Provided by:
Complete Family Eyecare
(402) 421-7773
1501 Pine Lake Rd Suite 1
Lincoln, NE

Data Provided by:
Wachal Pet Health Center
(402) 477-7877
201 Capital Beach Blvd Ste 10
Lincoln, NE

Data Provided by:
David Robert Paulus
(402) 476-1455
1021 N 27th St
Lincoln, NE
Specialty
Family Practice

Data Provided by:
Buettenback Chiropractic
(402) 476-8483
5533 NW 1st St
Lincoln, NE

Data Provided by:
Advanced Chiropractic Solutions
(402) 328-0028
3700 S 9th St
Lincoln, NE

Data Provided by:
Tarnick Chiropractic & Acupuncture
(402) 936-7292
5630 S. 84th St.
Lincoln, NE

Data Provided by:
Maryam Mahmoodian
(402) 476-1455
1021 N 27th St
Lincoln, NE
Specialty
Family Practice

Data Provided by:
Bogdan Derylo
(402) 466-8259
307 North 46 Street
Lincoln, NE
Specialty
Internal Medicine, Nephrology

Data Provided by:
Data Provided by:

Kidney Cancer

Provided By:

SUNDAY, May 31 (HealthDay News) -- Using a combination of the drugs temsirolimus (Torisel) and Bryostatin appears to be safe in patients with metastatic kidney cancer, according to early data from 25 patients in a phase 1 trial.

The researchers said a pathway known as mTOR signaling promotes tumor cell proliferation and tumor blood vessel development. The temsirolimus-bryostatin combination blocks two portions of the mTOR signaling pathway, and the early data suggests the drugs may be active in patients with rare forms of renal cell cancer that are less likely to respond to other therapies.

"We have certainly seen sustained responses with this combination, which are encouraging," Dr. Elizabeth Plimack, a medical oncologist and attending physician at Fox Chase Cancer Center in Philadelphia, said in a news release from the center.

"Patients with non-clear cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib [Sutent] and sorafenib [Nexavar], as patients with clear cell renal cell. So there is an unmet need for therapy for these patients. We've seen that this combination may be active to some degree for them," Plimack said.

The findings were to be presented Sunday at the American Society of Clinical Oncology annual meeting, in Orlando, Fla.

The trial is still enrolling new patients.

More information

The American Cancer Society has more about kidney cancer.

SOURCE: Fox Chase Cancer Center, news release, May 31, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com